Accumulation of tissue factor in endothelial cells induces cell apoptosis, mediated through p38 and p53 activation

Thrombosis and Haemostasis

Volumn 114, Issue 2, 2015, Pages 364-378

  Elkeeb, Azza M ^a   Collier, Mary E W ^a,b   Maraveyas, Anthony ^a   Ettelaie, Camille ^a  

^a UNIVERSITY OF HULL   (United Kingdom)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

Apoptosis; P38 MAP kinase; P53 activation; Serine phosphorylation; Tissue factor

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; CYCLIN D1; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN BAX; PROTEIN P53; THROMBOPLASTIN; 4-(4-FLUOROPHENYL)-2-(4-HYDROXYPHENYL)-5-(4-PYRIDYL)IMIDAZOLE; BAX PROTEIN, HUMAN; CCND1 PROTEIN, HUMAN; HYBRID PROTEIN; IMIDAZOLE DERIVATIVE; MESSENGER RNA; OLIGOPEPTIDE; PYRIDINE DERIVATIVE; SERYL-LEUCYL-ISOLEUCYL-GLYCYL--ARGINYL-LEUCINAMIDE; SMALL INTERFERING RNA; TP53 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MEMBRANE MICROPARTICLE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; TUNEL ASSAY; UPREGULATION; WESTERN BLOTTING; AMINO ACID SUBSTITUTION; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; BLOOD; BREAST TUMOR; CARDIOVASCULAR DISEASE; CELL CULTURE; COMPARATIVE STUDY; CORONARY BLOOD VESSEL; CYTOLOGY; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; METABOLISM; PATHOLOGY; PHYSIOLOGY; REPORTER GENE; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

AMINO ACID SUBSTITUTION; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BREAST NEOPLASMS; CARDIOVASCULAR DISEASES; CELL LINE, TUMOR; CELL-DERIVED MICROPARTICLES; CELLS, CULTURED; CORONARY VESSELS; CYCLIN D1; ENDOTHELIAL CELLS; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION REGULATION; GENES, REPORTER; HUMANS; IMIDAZOLES; MAP KINASE SIGNALING SYSTEM; OLIGOPEPTIDES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PYRIDINES; RECOMBINANT FUSION PROTEINS; RNA INTERFERENCE; RNA, MESSENGER; RNA, SMALL INTERFERING; THROMBOPLASTIN; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84940039262     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH14-09-0795     Document Type: Article

References (59)

1. Greeno EW, et al. Apoptosis is associated with increased cell surface tissue factor procoagulant activity. Lab Invest 1996; 75: 281–289.
2. Bombeli T, et al. Apoptotic vascular endothelial cells become procoagulant. Blood 1997; 89: 2429–2442.
3. Collier ME, Ettelaie C. Regulation of the incorporation of tissue factor into microparticles by serine phosphorylation of the cytoplasmic domain of tissue factor. J Biol Chem 2011; 286: 11977–11984.
4. Macey MG, et al. Microparticle formation after exposure of blood to activated endothelium under flow. Cytometry A 2010; 77: 761–768.
5. Morel O, et al. Endothelial cell activation contributes to the release of procoagulant microparticles during acute cardiac allograft rejection. J Heart Lung Transplant 2008; 27: 38–45.
6. Leroyer AS, et al. Cellular origins and thrombogenic activity of microparticles isolated from human atherosclerotic plaques. J Am Coll Cardiol 2007; 49: 772–777.
7. Pradier A, Ettelaie C. The influence of exogenous tissue factor on the regulators of proliferation and apoptosis in endothelial cells. J Vasc Res 2008; 45: 19–32.
8. Peng W, et al. The effects of small interfering RNA-targeting tissue factor on an in vitro model of neovascularisation. Mol Vis 2013; 19: 1296–1303.
9. Collier ME, Ettelaie C. Induction of endothelial cell proliferation by recombinant and microparticle-tissue factor involves beta1-integrin and extracellular signal regulated kinase activation. Arterioscler Thromb Vasc Biol 2010; 30: 1810–1817.
10. Dorfleutner A, et al. Cross-talk of integrin α3β1 and tissue factor in cell migration. Mol Biol Cell 2004; 15: 4416–4425.
11. Versteeg HH, et al. Inhibition of tissue factor signaling suppresses tumor growth. Blood 2008; 111: 190–199.
12. Collier ME, et al. Influence of exogenous tissue factor on estrogen receptor α expression in breast cancer cells: involvement of β1-integrin, PAR2, and mitogenactivated protein kinase activation. Mol Cancer Res 2008; 6: 1807–1818.
13. van den Berg YW, et al. Alternatively spliced tissue factor induces angiogenesis through ligation. Proc Natl Acad Sci USA 2009; 106: 19497–19502.
14. Kocatürk B, et al. Alternatively spliced tissue factor promotes breast cancer growth in a β1 integrin-dependent manner. Proc Natl Acad Sci USA 2013; 110: 11517–11522.
15. Ettelaie C, et al. p38α phosphorylates serine 258 within the cytoplasmic domain of tissue factor and prevents its incorporation into cell-derived microparticles. Biochim Biophys Acta 2013; 1833: 613–621.
16. Nawroth PP, Stern DM. Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J Exp Med 1986; 163: 740–745.
17. Noguchi M, et al. Correlation between antigenic and functional expression of tissue factor on the surface of cultured human endothelial cells following stimulation by lipopolysaccharide endotoxin. Thromb Res 1989; 55: 87–97.
18. Clauss M, et al. Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J Exp Med 1990; 172: 1535–1545.
19. Østerud B, Bjorklid E. Tissue factor in blood cells and endothelial cells. Front Biosci (Elite E) 2012; 4: 289–299.
20. Yu J, et al. Contribution of host-derived tissue factor to tumor neovascularisation. Arterioscler Thromb Vasc Biol 2008; 28: 1975–1981.
21. Collier MEW, et al. Microparticle-associated tissue factor is recycled by endothelial cells resulting in enhanced surface TF activity. Thromb Haemost 2013; 111: 647–655
22. Kawamoto T, et al. Tumor-derived microvesicles induce proangiogenic phenotype in endothelial cells via endocytosis. PLoS One 2012; 7: e34045.
23. Dasgupta SK, et al. Developmental endothelial locus-1 (Del-1) mediates clearance of platelet microparticles by the endothelium. Circulation 2012; 125: 1664–1672.
24. Hansen CB, et al. Tissue factor-mediated endocytosis, recycling, and degradation of factor VIIa by a clathrin-independent mechanism not requiring the cytoplasmic domain of tissue factor. Blood 2001; 97: 1712–1720.
25. Jesel L, et al. Microparticles in atrial fibrillation: a link between cell activation or apoptosis, tissue remodelling and thrombogenicity. Int J Cardiol 2013; 168: 660–669.
26. Morel O, et al. Increased levels of procoagulant tissue factor-bearing microparticles within the occluded coronary artery of patients with ST-segment elevation myocardial infarction: role of endothelial damage and leukocyte activation. Atherosclerosis. 2009; 04: 636–641.
27. Martin S, et al. Shed membrane particles from T lymphocytes impair endothelial function and regulate endothelial protein expression. Circulation. 2004; 109: 1653–1659.
28. Jung C, et al. Circulating endothelial and platelet derived microparticles reflect the size of myocardium at risk in patients with ST-elevation myocardial infarction. Atherosclerosis 2012; 221: 226–231.
29. Chironi GN, et al. Endothelial microparticles in diseases. Cell Tissue Res 2009; 335: 143–151.
30. Houston P, et al. Fluid shear stress induction of the tissue factor promoter in vitro and in vivo is mediated by Egr-1. Arterioscler Thromb Vasc Biol 1999; 19: 281–289.
31. Ettelaie C, et al. Characterisation of physical properties of tissue factor-containing microvesicles and a comparison of ultracentrifuge-based recovery procedures. J Extracell Vesicles. 2014 Aug 13;3. doi: 10.3402/jev.v3.23592.
32. Ray B, et al. Plasma tissue factor is a predictor for restenosis after femoropopliteal angioplasty. Br J Surg 2007; 94: 1092–1095.
33. Nielsen VG, et al. Qualitative thrombelastographic detection of tissue factor in human plasma. Anesth Analg 2007; 104: 59–64.
34. Ettelaie C, et al. A. Enhanced binding of tissue factor-microparticles to collagen-IV and fibronectin leads to increased tissue factor activity in vitro. Thromb Haemost 2013; 109: 61–71.
35. Bonnekoh B, et al. Colorimetric growth assay for epidermal cell cultures by their crystal violet binding capacity. Arch Dermatol Res 1989; 281: 487–490.
36. Ettelaie C, et al. Differential functions of tissue factor in the trans-activation of cellular signalling pathways. Atherosclerosis 2007; 194: 88–101.
37. Komarov PG, et al. A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science 1999; 285: 1733–1737.
38. Essmann F, et al. Apoptosis resistance of MCF-7 breast carcinoma cells to ionizing radiation is independent of p53 and cell cycle control but caused by the lack of caspase-3 and a caffeine-inhibitable event. Cancer Res 2004; 64: 7065–7072.
39. Wang S, et al. Doxorubicin induces apoptosis in normal and tumor cells via distinctly different mechanisms. intermediacy of H(2)O(2)- and p53-dependent pathways. J Biol Chem. 2004; 279: 25535–25543.
40. Livak KG, Schmittgen TD. Analysis of relative gene Expression Data Using Real-Time Quantitative PCR and the 2-ΔΔCT Method Methods 2001; 25: 402–408.
41. Albrektsen T, et al. Transcriptional program induced by factor VIIa-tissue factor, PAR1 and PAR2 in MDA-MB-231 cells. J Thromb Haemost 2007; 5: 1588–1597.
42. Suen JY, et al. Profiling gene expression induced by protease-activated receptor 2 (PAR2) activation in human kidney cells. PLoS One. 2010; 5: e13809.
43. Banfi C, et al. Tissue factor induction by protease-activated receptor 1 requires intact caveolin-enriched membrane microdomains in human endothelial cells. J Thromb Haemost 2007; 5: 2437–2444.
44. Frentzou GA, et al. Differential induction of cellular proliferation, hypertrophy and apoptosis in H9c2 cardiomyocytes by exogenous tissue factor. Mol Cell Biochem 2010; 345: 119–130.
45. Aharon A, et al. Monocyte-derived microparticle and exosomes induce procoagulant and apoptotic effects on endothelial cells. Thromb Haemost 2008; 100: 878–885.
46. Bulavin DV, et al. Phosphorylation of human p53 by p38 kinase coordinates N-terminal phosphorylation and apoptosis in response to UV radiation. EMBO J 1999; 18: 6845–6854.
47. Sanchez-Prieto R, et al. A role for the p38 mitogen-acitvated protein kinase pathway in the transcriptional activation of p53 on genotoxic stress by chemotherapeutic agents. Cancer Res 2000; 60: 2464–2472.
48. Kishi H, et al. Osmotic shock induces G1 arrest through p53 phosphorylation at Ser33 by activated p38MAPK without phosphorylation at Ser15 and Ser20. J Biol Chem 2001; 276: 39115–39122.
49. El-Deiry WS, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75: 817–25.
50. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997; 88, 323–331.
51. Gottlieb TM, Oren M. p53 in growth control and neoplasia. Biochim Biophys Acta 1996; 1287: 77–102.
52. Yoshida K, et al. Protein kinase C delta regulates Ser46 phosphorylation of p53 tumor suppressor in the apoptotic response to DNA damage. J Biol Chem 2006; 281: 5734–5740.
53. Saito S, et al. Phosphorylation site interdependence of human p53 post-translational modifications in response to stress. J Biol Chem 2003; 278: 37536–37544.
54. Kurihara A, et al. Ser46 phosphorylation of p53 is not always sufficient t o induce apoptosis: multiple mechanisms of regulation of p53-dependent apoptosis. Genes Cells 2007; 12: 853–861.
55. Bulavin DV, et al. Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity. Nat Genet 2002; 31: 210–215.
56. Takekawa M, et al. p53-inducible wip1 phosphatase mediates a negative feedback regulation of p38 MAPK-p53 signaling in response to UV radiation. EMBO J 2000; 19: 6517–6526.
57. Cohen M, et al. Trophoblastic p53 is stabilised by a cis-trans isomerisation necessary for the formation of high molecular weight complexes involving the N-terminus of p53. Biochimie 2008; 90: 855–862.
58. Zacchi P, et al. The prolyl isomerase Pin1 reveals a mechanism to control p53 functions after genotoxic insults. Nature 2002; 419: 853–857.
59. Zheng H, et al. The prolyl isomerase Pin1 is a regulator of p53 in genotoxic response. Nature 2002; 419: 849–853.